Antag Therapeutics is a biopharmaceutical company focused on developing innovative treatments for obesity. The company is advancing its clinical pipeline with AT-7687, a novel, once-weekly subcutaneous therapy that targets the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) to aid in weight loss. Based in Copenhagen, Denmark, Antag Therapeutics is committed to expanding its portfolio of injectable therapies to address metabolic disorders.
Leadership & Board
Current Number of Employees23
Current LinkedIn Followers4,755
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$164M
Total Amount Raised$164M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$80M
Latest Funding Amount$80M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Antag Therapeutics had 23 employees as of October 5, 2026. The number of employees increased by 0 (0.00%) week-over-week.
23Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Antag Therapeutics had 4,755 followers as of October 5, 2026. The number of followers increased by 20 (0.42%) week-over-week.
4,755Latest Followers Count
20(0.42%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.